Log in
Enquire now
Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

A biopharmaceutical company focusing on the discovery, development, and commercialization of RNAi therapeutics for treating rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS) diseases.

OverviewStructured DataIssuesContributors

Contents

alnylam.com
alnylam.com/alnylam-japan
Is a
Company
Company
Organization
Organization

Company attributes

Industry
RNA
RNA
Biomedical engineering
Biomedical engineering
Technology
Technology
RNA-based and RNA-targeted therapeutics
RNA-based and RNA-targeted therapeutics
Biology
Biology
...
Location
Norton, Massachusetts
Norton, Massachusetts
Cambridge, Massachusetts
Cambridge, Massachusetts
Canada
Canada
United States
United States
Tokyo
Tokyo
United Kingdom
United Kingdom
B2X
B2C
B2C
B2B
B2B
0
CEO
‌
John Maraganore
‌
YVONNE GREENSTREET
0
Founder
‌
Phillip D. Zamore
0
‌
Phillip Sharp
0
‌
Robert Langer
‌
Thomas Tuschl
Paul Schimmel
Paul Schimmel
‌
David Bartel
‌
John Clarke
0
AngelList URL
angel.co/alnylam-ph...maceuticals0
Pitchbook URL
pitchbook.com/profiles.../42020-38
Legal Name
Alnylam Pharmaceuticals, Inc.
Legal classification
Corporation
Corporation
Date Incorporated
March 26, 2018
Number of Employees (Ranges)
1,001 – 5,000
Email Address
info@alnylam.com0
businessdevelopment@alnylam.com0
medinfo@alnylam.com0
investors@alnylam.com0
clinicaltrials@alnylam.com0
Phone Number
+414156135000
+312036978610
+101209703470
+187725695260
+184454383550
+183325627480
+161755182000
Number of Employees
1,665
Full Address
675 West Kendall St Cambridge, MA 02142
Grafenauweg 4 6300 Zug Switzerland
Cross Towers, 20e verdieping Antonio Vivaldistraat 150 1083 HP Amsterdam Nederland
Braywick Gate Braywick Rd Maidenhead SL6 1DA, UK
20 Commerce Way Norton, MA 02766 USA
11th Floor of Pacific Century Place Marunouchi 1-11-1 Marunouchi, Chiyoda-ku Tokyo 100-6211 Japan
CIK Number
1,178,6700
Investors
ARCH Venture Partners
ARCH Venture Partners
Takeda Pharmaceutical Company
Takeda Pharmaceutical Company
Merck Group
Merck Group
Blackstone Life Sciences
Blackstone Life Sciences
Cardinal Partners
Cardinal Partners
GSO Capital Partners
GSO Capital Partners
Abingworth
Abingworth
Ridgeback Capital
Ridgeback Capital
...
DUNS Number
1155244100
IRS Number
770,602,6610
Founded Date
2002
Fax Number
617.551.81010
Total Funding Amount (USD)
886,100,000
Latest Funding Round Date
April 17, 2020
Competitors
Avidity Biosciences
Avidity Biosciences
Kernal Biologics
Kernal Biologics
Stock Symbol
ALNY0
Exchange
Nasdaq
Nasdaq
0
Board of Directors
‌
Marsha H. Fanucci
0
Olivier Brandicourt
Olivier Brandicourt
0
‌
YVONNE GREENSTREET
0
‌
Amy W. Schulman
0
‌
Dennis A. Ausiello
0
‌
Margaret A. Hamburg
0
‌
Michael W. Bonney
0
‌
David E.I. Pyott
0
CTO
Al Boyle
Al Boyle
0
CFO
‌
jeff poulton
0
Latest Funding Type
Private equity
Private equity
CAGE Code
45SR10
Patents Assigned (Count)
315
Legal Entity Identifier
529900S3ZI14OWRJII500
Wellfound ID
alnylam-pharmaceuticals0
Country
Japan
Japan
United States
United States
Headquarters
Cambridge, Massachusetts
Cambridge, Massachusetts

Other attributes

Company Operating Status
Active
Previous Name
ALNYLAM PHARMACEUTICALS INC0
SIC Code
2,8340
Ticker Symbol
ALNY
Wikidata ID
Q16974682

Alnylam Pharmaceuticals is a biopharmaceutical company focusing on the discovery, development, and commercialization of RNAi therapeutics for treating rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS) diseases that is headquartered in Boston, Massachusetts and was founded in 2002 by David Bartel, John Clarke, Paul Schimmel, Phillip D. Zamore, Phillip Sharp, Robert Langer, and Thomas Tuschl.

RNAi Therapeutics - How this New Class of Medicines Works.

Products
ONPATTRO

ONPATTRO (patisiran) is a prescription medicine for treating polyneuropathy in adults caused by hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). The most common side effects of patients taking ONPATTRO are respitory infections (colds, sinus infections, nasal congestion, and infusion-related reactions). ONPATTRO is known to lower vitamin A levels circulating in the blood. It is made to decrease the amount of TTR protein created in the liver. TTR protein levels were shown to decrease by 84% on average in patients taking ONPATTRO for 18 months.

GIVLAARI

GIVLAARI (givosiran) prescription medicine for treating adult acute hepatic porphyria (AHP). The most common side effects of adults taking GIVLAARI include injection site reactions and nausea. GIVLAARI reduces the amount of ALAs1 present in the liver which leads to the lowering of ALA and PBG neurotoxins associated with the AHP symptoms and attacks. A six month study showed that patients treated with GIVLAARI hadreduced days of hemin and a 70% reduction in AHP attacks (average of 1.9 AHP attacks) compared to the placebo group (average of 6.5 AHP attacks) not receiving GIVLAARI.

Product Pipeline
Fitusiran

Fitusiran (ALN-AT3) is a RNAi therapeutic for treating hemophilia and rare bleeding disorders (RBDs). It uses the company's Enhanced Stabilization Chemistry (ESC)-GalNAc delivery platform and is delivered subcutaneously to target antithrombin (AT). Sanofi Genzyme is helping Alnylam Pharmaceuticals is the development of Fitusiran.

Inclisiran

Inclisiran (ALN-PCSsc) is a RNAi therapeutic for treating hypercholesterolemia. It uses the company's Enhanced Stabilization Chemistry (ESC)-GalNAc delivery platform and is delivered subcutaneously to target proprotein convertase subtilisin kexin type 9 (PCSK9). Novartis is working with Alnylam Pharmaceuticals to develop Inclisiran.

Lumasiran

Lumasiran (ALN-GO1) is a RNAi therapeutic for treating Primary Hyperoxaluria Type 1 (PH1). It uses the company's Enhanced Stabilization Chemistry (ESC)-GalNAc delivery platform and is delivered subcutaneously to target glycolate oxidase (GO).

Vutrisiran

Vutrisiran (SLN-TTRsc02) is a RNAi therapeutic for treating transthyretin-mediated (ATTR) amyloidosis. It uses the company's Enhanced Stabilization Chemistry (ESC)-GalNAc delivery platform and is delivered subcutaneously to target transthyretin (TTR).

Cemdisiran

Cemdisiran (ALN-CC5) is a RNAi therapeutic for treating complement-mediated diseases. It uses the company's Enhanced Stabilization Chemistry (ESC)-GalNAc delivery platform and is administered subcutaneously for targeting the C5 component of the complement pathway.

ALN-AAT02

ALN-AAT02 is a RNAi therapeutic for treating AAT deficiency-associated liver disease (alpha-1 liver disease). It uses the company's Enhanced Stabilization Chemistry-Plus (ESC+)-GalNAc delivery platform and is delivered subcutaneously to target alpha-1 antitrypsin (AAT).

ALN-HBV02

ALN-HBV02 is a RNAi therapeutic for treating chronic hepatitis B virus infection. It uses the company's Enhanced Stabilization Chemistry-Plus (ESC+)-GalNAc delivery platform and is delivered subcutaneously for targeting the hepatitis B virus (HBV) genome. ALN-HBV02 is made to inhibit hepatitis B surface antigen (HBsAg) and the expression of all other HBV proteins. Vir Biotechnology is working with Alnylam Pharmaceuticals to develop ALN-HBV02.

ALN-AGT

ALN-AGT is a RNAi therapeutic for treating hypertension. Is uses the company's Enhanced Stabilization Chemistry Plus (ESC+)-GalNAc delivery platform and is delivered subcutaneously to target angiotensinogen (AGT).

ALN-HSD

ALN-HSD is a RNAi therapeutic for treating non-alcoholic steatohepatitis (NASH). It uses the company's Enhanced Stabilization Chemistry-Plus (ESC+)-GalNAc delivery platform and is delivered subcutaneously to target HSD17B13. Regeneron is working with Alnylam Pharmaceuticals in the development of ALN-HSD.

ALN-COV

ALN-COV is a RNAi therapeutic for treating and preventing COVID-19. It uses a novel conjugate lung delivery system in combination with the company's Enhanced Stabilization Chemistry (ESC) delivery platform and it delivered through inhalation to target the SARS-COV-2 viral genome. Vir Biotechnology is working with Alnylam Pharmaceuticals in the development of ALN-COV.

Awards
Innovative Growth Companies 2016

Alnylam Pharmaceuticals was named #100 on the Forbes Innovative Growth Companies 2016 list. The company did not make the Forbes Innovative Growth Companies 2017 list.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

2020: Extraordinary Year, Extraordinary People

https://youtu.be/1UWERwTzdhk

Web

January 25, 2021

Alnylam Challengers - A Community Impact Program to Improve Health Access in Underserved Communities

https://youtu.be/hIiEeIpDi9Q

Web

October 13, 2021

References

Find more companies like Alnylam Pharmaceuticals

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.